Ursodeoxycholic Acid Confers Neuroprotection in Rats With Acute Cervical SCI and Attenuates NLRP3/Caspase-1/GSDMD Pyroptotic Signaling.
4 affiliations
- 1School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- 2Department of Rehabilitation Medicine, General Hospital of Western Theater Command, Chengdu, China.
- 3College of Medicine, Southwest Jiaotong University, Chengdu, China.
- 4Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, China.
Abstract
Spinal cord injury (SCI) leads to significant and enduring functional limitations for patients. Secondary injury is a pivotal determinant of functional recovery after SCI, with pyroptosis driven by the NLRP3 inflammasome and its downstream inflammatory cascade representing a crucial contributor to this process. Ursodeoxycholic acid (UDCA), an endogenous secondary bile acid, displays neuroprotective activity through antioxidant and anti-inflammatory actions and may suppress pyroptosis. This study aimed to explore the neuroprotective effects of UDCA against SCI and its underlying mechanisms. BV2 microglia were treated with LPS and UDCA, either individually or concurrently. Cell viability and NLRP3 inflammasome protein expression were evaluated by CCK-8 assay and immunofluorescence, respectively. Additionally, following establishment of a rat model of C5 cervical SCI, UDCA was administered by oral gavage for 7 days. Functional recovery, histopathological damage, key protein expression in the NLRP3/Caspase-1/GSDMD pyroptosis pathway, and downstream inflammation were analyzed using various techniques, including behavioral evaluation (Cylinder Rearing test), HE staining, Western blot, immunofluorescence, and ELISA. Results showed that appropriate concentrations of UDCA improved BV2 cell viability and inhibited LPS-stimulated NLRP3 upregulation. Oral gavage of UDCA was associated with better forelimb motor function and attenuated spinal histopathological injury in rats with acute C5 cervical SCI. Furthermore, this treatment correlated with altered abundance of key components within the SCI‑activated NLRP3/Caspase‑1/GSDMD pathway, lower Iba‑1 expression, and diminished serum concentrations of IL‑18, IL‑1β, and TNF‑α, suggestive of attenuated neural pyroptosis and dampening of excessive postinjury inflammation. Collectively, UDCA mitigates secondary injury and improves forelimb function in an acute C5 cervical SCI model, alongside attenuation of NLRP3/Caspase-1/GSDMD-mediated pyroptosis and subsequent inflammation. Targeting pyroptosis, UDCA holds promise as a novel therapeutic candidate for SCI.
Related
- Apigenin promotes neuronal norepinephrine release via GPR30/PLCβ1-Ca2+-Syt1 signaling to enhance astrocytic lactate and exert neuroprotection in D-galactose-induced cognitive impairment
- Inhibition of Panx1/P2X7R/NLRP3 Signaling Attenuates Bone Cancer Pain and Spinal Microglial Activation
- Gui Gan Shen Mai Yin attenuates cardiac hypertrophy and dysfunction in association with mitochondrial homeostasis and the PI3K/AKT1 signaling pathway
- Inhibition of spinal astrocytic GPR177 attenuates neuropathic pain by modulating C3/C3aR signaling in male rats
- Pimpinella brachycarpa extract attenuates periodontal inflammation by modulating the PI3K/Akt–NF-κB signaling pathway
BibTeX
@article{song2026ursodeoxycholic,
title = {{Ursodeoxycholic Acid Confers Neuroprotection in Rats With Acute Cervical SCI and Attenuates NLRP3/Caspase-1/GSDMD Pyroptotic Signaling.}},
author = {Honghu Song and Xiaomin Hu and Dan Liu and Linjie Wang and Li Zhu and Wenchun Wang and Rongnan Hu and Jiayan Zhong and Jiancheng Liu and Rizhao Pang and Anren Zhang},
journal = {Journal of biochemical and molecular toxicology},
year = {2026},
month = oct,
doi = {10.1002/jbt.71157},
url = {https://europepmc.org/article/MED/42952279},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ursodeoxycholic Acid Confers Neuroprotection in Rats With Acute Cervical SCI and Attenuates NLRP3/Caspase-1/GSDMD Pyroptotic Signaling.
AU - Honghu Song
AU - Xiaomin Hu
AU - Dan Liu
AU - Linjie Wang
AU - Li Zhu
AU - Wenchun Wang
AU - Rongnan Hu
AU - Jiayan Zhong
AU - Jiancheng Liu
AU - Rizhao Pang
AU - Anren Zhang
PY - 2026
DA - 2026/10/28
JO - Journal of biochemical and molecular toxicology
DO - 10.1002/jbt.71157
UR - https://europepmc.org/article/MED/42952279
AB - Spinal cord injury (SCI) leads to significant and enduring functional limitations for patients. Secondary injury is a pivotal determinant of functional recovery after SCI, with pyroptosis driven by the NLRP3 inflammasome and its downstream inflammatory cascade representing a crucial contributor to this process. Ursodeoxycholic acid (UDCA), an endogenous secondary bile acid, displays neuroprotective activity through antioxidant and anti-inflammatory actions and may suppress pyroptosis. This study aimed to explore the neuroprotective effects of UDCA against SCI and its underlying mechanisms. BV2 microglia were treated with LPS and UDCA, either individually or concurrently. Cell viability and NLRP3 inflammasome protein expression were evaluated by CCK-8 assay and immunofluorescence, respectively. Additionally, following establishment of a rat model of C5 cervical SCI, UDCA was administered by oral gavage for 7 days. Functional recovery, histopathological damage, key protein expression in the NLRP3/Caspase-1/GSDMD pyroptosis pathway, and downstream inflammation were analyzed using various techniques, including behavioral evaluation (Cylinder Rearing test), HE staining, Western blot, immunofluorescence, and ELISA. Results showed that appropriate concentrations of UDCA improved BV2 cell viability and inhibited LPS-stimulated NLRP3 upregulation. Oral gavage of UDCA was associated with better forelimb motor function and attenuated spinal histopathological injury in rats with acute C5 cervical SCI. Furthermore, this treatment correlated with altered abundance of key components within the SCI‑activated NLRP3/Caspase‑1/GSDMD pathway, lower Iba‑1 expression, and diminished serum concentrations of IL‑18, IL‑1β, and TNF‑α, suggestive of attenuated neural pyroptosis and dampening of excessive postinjury inflammation. Collectively, UDCA mitigates secondary injury and improves forelimb function in an acute C5 cervical SCI model, alongside attenuation of NLRP3/Caspase-1/GSDMD-mediated pyroptosis and subsequent inflammation. Targeting pyroptosis, UDCA holds promise as a novel therapeutic candidate for SCI.
SN - 1095-6670
SN - 1099-0461
ER -